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Purpose: To compare the effect of oral acetazolamide and topical 2% dorzolamide in prevention 
of ocular hypertension after scleral tunnel cataract surgery.
Setting: Ophthalmic department, Sana’a University, Yemen Sana’a from March 2007 to 
October 2007.
Methods: This prospective double-blind, randomized study included 150 eyes undergoing 
scleral tunnel cataract surgery with hard posterior chamber intraocular implantation. Methylcel-
lulose was used as the viscoelastic in all surgery cases. Patients were assigned to one of three 
groups: group 1: topical gentamicin eye drops (control; n = 52); group 2: systemic acetazolamide 
250 mg (n = 45); and group 3: topical 2% dorzolamide (n = 53). Acetazolamide patients received 
one 250 mg tablet, one hour before surgery, then half a tablet every eight hours. A topical 
dorzolamide 2% or gentamicin was applied in one drop one hour before surgery then every eight 
hours, for three days postoperatively. Intraocular pressures (IOP) were measured by Goldman 
applanation tonometry one hour preoperatively and 16, 24, and 48 hours postoperatively.
Results: At 16 hours, IOP between the three groups increased significantly with a statistically 
significant p-value of 0.008, but the mean IOP of acetazolamide patients was less than other 
groups. IOP nearly returned to the normal level 24 and 48 hours postoperatively, but this was 
not statistically significant (p = 0.452 and 0.138, respectively).
Conclusion: Acetazolamide offers better IOP control than topical dorzolamide 2% in preventing 
ocular hypertension after scleral tunnel cataract surgery.
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Introduction
A major reason for subsequent day assessment is to detect raised intraocular pressure 
(IOP), which complicates almost 8% of all cataract extractions.1 Postoperative IOP 
increase is the most frequent short-term complication of cataract surgery.2–4 It has 
become a major concern as an increasing number of cataract patients are having surgery 
in an outpatient setting and are discharged soon after surgery. Increasing demand for 
cataract surgery is resulting in a greater emphasis on high volume day-case procedures, 
where postoperative care varies widely from center to center, with little evidence-based 
practice. It is common for patients to be routinely assessed on the day after surgery, 
necessitating a further hospital visit.5,6
Postoperative assessment on the day of surgery will detect not only a spike of IOP, 
but also most early surgically related complications such as wound leak, iris prolapse, 
and a dislocated intraocular lens (IOL). Viscoelastic substances are widely used in small 
incision cataract surgery with several advantages. It has the maintenance of the anterior Clinical Ophthalmology 2009:3 358
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chamber space, protection of the corneal endothelium, and 
facilitation of the surgical procedure, especially during 
anterior capsulotomy and IOL implantation. It has some 
disadvantage of causing an increase in IOP within the first 
24 hours after cataract surgery.7–16 However, in small-incision 
cataract surgery there are occasional spikes of 30 mmHg or 
higher with the use of sodium hyaluronate.17 Chakraborty and 
colleagues recommended the routine use of oral acetazol-
amide after phacoemulsification.18 Systemic carbonic anhy-
drase inhibitors (CAIs) are associated with adverse effects 
such as acid-base disturbance, hypersensitivity reactions, and 
fatal aplastic anemia.11,19–21
We report a prospective double-blind randomized study 
where acetazolamide was given in select patients as a prophy-
lactic IOP-lowering treatment after manual sutureless scleral 
tunnel cataract surgery with posterior chamber intraocular 
lens (PC IOL) implantation.
Patients and methods
This prospective double-blind randomized study comprised 
150 eyes from 150 consecutive patients (68 males and 
82 females) with unilateral uncomplicated age-related cata-
ract. All patients were scheduled for manual sutureless scleral 
tunnel cataract surgery with poly(methyl methacrylate) 
(PMMA) hard posterior chamber IOL implantation. Exclu-
sion criteria included patients with history of glaucoma or 
lens-induced glaucoma and ocular hypertension more than 
25 mmHg. Patients presenting with IOP less than 10 mmHg 
were excluded. Patients with uveitis, sublaxating or dislo-
cating crystalline lens, or previous ocular surgery or laser 
treatment were not involved in this study. Intraoperative 
posterior capsule rupture or vitreous loss was eliminated from 
the study. All patients with age-related cataract including 
hypermature and pseudoexfoliation syndrome with cataract 
were included in this study.
The preoperative baseline IOP was measured before using 
dilating drops, then Goldmann applanation tonometry one 
hour before surgery. Patients were randomly assigned to one 
of three groups based on the type of IOP-lowering medica-
tion given at one hour before surgery: group 1: one drop of 
gentamicin (control eyes); group 2: one tablet of acetazolamide 
(Cidamex) 250 mg; group 3: one drop of dorzolamide 2% 
(Xola) instead of apraclonidine due to its unavailability in 
the Yemen market. The ophthalmic nurse in our study was the 
only one to know which group received one of the three types 
of medications one hour before surgery immediately after 
taking the base IOP. All patients were operated on in the same 
fashion by the same consultant ophthalmologist. Dilating drops 
(phenylephrine 2.5%, tropicamide 0.5%) were instilled in the 
operated eye approximately one to two hours before surgery. 
At the time of this study, phacoemulsification was not started 
yet and extracapsular cataract surgery with PC IOL was the 
standard technique for cataract surgery in our department.
Peribulbar anesthesia of lidocaine hydrochloride 
2% was used in all cases. The operated eye was steril-
ized with povidone–iodine 5% solution for two minutes. 
After peribulbar anesthesia was administered, a fornix-
based conjunctival flap was done, followed by adequate 
electrocautery for homeostasis, and then a 6 to 7 mm scleral 
tunnel incision curving away from the limbus “frown “ 
incision from 11 o’clock to 1 o’clock position was performed 
by the same surgeon. Another temporal 2-mm corneal 
tunnel paracentesis incision was applied. The viscoelastic 
(methylcellulose) substance was injected into the anterior 
chamber. This was followed by capsulorrhexis, hydrodissec-
tion, and prolapse of the nucleus into the anterior chamber. 
Delivery of the nucleus using irrigating victus was followed 
by irrigation aspiration of the cortical materials remnants and 
cleaning of the capsular bag using Ringer’s lactate solution. 
The anterior chamber and capsular bag was expanded with 
the viscoelastic substance and a hard PMMA IOL implanted 
in the capsular bag. The viscoelastic substance was aspirated 
from the anterior chamber using an irrigation/aspiration (I/A) 
cannula. The incision was left sutureless while the conjunc-
tiva was closed by electrocautery. No miotic agent was used 
intracamerally for all surgical patients. Capsule rupture did 
not occur in all cases. After surgery, the eye was patched after 
subconjunctival injection of gentamicin–dexamethasone.
After this, ophthalmic assistance was the administration 
of antiglaucoma drugs according to the subdivision of the 
patients, control group (gentamicin) eyedrops every eight 
hours, the second group received acetazolamide 250 mg half 
tablet every eight hours, while the third group received topical 
dorzolamide 2% (Xola) eyedrops every eight hours.
After 16 + 2 hours visits, dexamethasone 1% eye drops 
were used five times a day, then followed by measuring 
the IOP at 16, 24, and 48 hours after surgery. The IOP in 
the operated eye was measured by an ophthalmic resident 
unaware of the patient's group assignment using a Goldmann 
applanation tonometer.
The SPSS program (version 13; SPSS Inc., Chicago, 
IL, USA) was used to analyze the data of this study. Group 
comparisons of mean with standard deviation were associated 
with P-value in preoperative and postoperative IOP using a 
one-way ANOVA test. The mean IOP involving the standard 
deviation changes from preoperatively to 16 hours, and 24 to Clinical Ophthalmology 2009:3 359
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48 hours postoperatively were calculated by paired sample 
t-test. The preoperative P value was compared to those after 
16, 24, and 48 hours in each group by ANOVA tests.
Results
This study includes 150 eyes from 150 patients who had 
surgery between March 2007 and October 2007. All patients 
were Yemeni in origin. All surgeries were completed by 
one consultant ophthalmologist without intraoperative 
complications.
The mean age was almost equal in all groups with a male-to-
female ratio of 26:26 in the control group, 18:27 in the acetazol-
amide group, and 24:29 in the dorzolamide group (Table 1).
Table 2 shows the mean preoperative and postopera-
tive IOP which peaked at 16 hours in all three groups and 
returned to nearly preoperative values by 48 hours. The 
mean IOP preoperatively was significantly lower in the 
dorzolamide group when compared between and within 
groups (p = 0.035). Sixteen hours postoperatively, the mean 
IOP was significantly lower in the acetazolamide group than 
in the control and dorzolamide groups, respectively, while 
within groups highly statistically significant (p = 0.008). 
At 24 and 48 hours IOP within groups (p = 0.452 and 0.138, 
respectively) returned to nearly basal IOP.
The mean difference in IOP changes from preoperatively 
to 16 hours, and 24 to 48 hours, postoperatively is shown in 
Table 3. The mean difference in IOP was almost equal in all 
groups without significant difference. At 24 and 48 hours, 
the mean IOP went down in all groups with no significant 
difference between groups.
Six (11.4%) control patients had an IOP of  30 mmHg 
or higher at 16 hours compared with seven (12.3%) dorzol-
amide patients and only one (2.2%) acetazolamide patient. 
All of those patients with a previous diagnosis did not have 
glaucoma or ocular hypertension in the operated eye.
Discussion
We found in this study that acetazolamide controls the rising 
IOP in the first 48 hours of manual sutureless scleral tunnel 
cataract surgery with hard posterior chamber PMMA IOL 
implantation. IOP usually starts to rise two to four hours 
after surgery and lasts up to 24 hours, when most of the 
viscoelastic material has left the anterior chamber through the 
outflow channels.19–21 Some studies assessing the frequency 
of a clinically significant elevation in IOP after cataract 
surgery found IOP to be transiently raised in 2.3% to 8.9% 
of cases.19,22 Some causes contributing to elevated IOP after 
cataract surgery such as use of viscoelastic material23 and 
retained lens matter may also cause uveitis and shooting 
of IOP after surgery. Prostaglandin releases after cataract 
surgery also play a role in elevated IOP.19–22,24,25 Postoperative 
hyphema may occasionally cause an increased IOP by red 
blood cell blockage of the trabecular meshwork. Postopera-
tive increase in IOP may be associated with pain, corneal 
edema, optic nerve damage, and visual field loss in patients 
with pre-existing glaucoma. Various drugs, including the 
systemic CAIs, timolol, pilocarpine gel, intracameral acetyl-
choline, and carbachol have been studied as agents to prevent 
postoperative IOP spikes.24–31
One of the primary functions of the next-day review visit 
is to measure and treat significantly raised IOP. Discharging 
patients a few hours after surgery may miss several patient 
guidelines. Many patients at risk of significant morbidity 
from a persistently raised postoperative IOP may not be 
detected otherwise. A lot of studies done in this field so far 
have been to detect and treat early shooting of IOP postop-
eratively.
In this study, we found that the IOP peaked after 
16 hours postoperatively in the control (p = 0.000) and 
dorzolamide groups (p = 0.000), and acetazolamide patients 
had a statistically insignificant increase (p = 0.288), while 
IOP increased statistically significantly between groups 
(p = 0.008). This agrees with earlier studies in patients after 
extracapsular surgery in which IOP peaked six to eight 
hours postoperatively.32–35 There were a few patients in the 
control and dorzolamide groups whose IOP levels reached 
up to 40 mmHg during the first 16 hours and returned to 
preoperative levels by 48 hours. Conversely, there were two 
(3.8%) patients from the dorzolamide group and only one 
(1.9%) patient in the control group whose IOP was lower 
than 5 mmHg 16 hours postoperatively. Close examination 
of these cases revealed deep anterior chambers and no wound 
leak. Significantly, the IOP returned to normal after 48 hours 
postoperatively and no complications were reported. This 
finding may represent suboptimal anterior chamber infla-
tion at the conclusion of surgery36 or ciliary body shutdown 
secondary to the peribulbar anesthesia.
Table 1 Patient characteristics
Character  Control 
group
Acetazolamide 
group
Dorzolamide 
group
no of eyes 52 45 53
Mean age (years) 63.05 ± 9.53 60.15 ± 12.08 63.88
Age range (years) 46 59 55
sex (M:F) 26:26 18:27 24:29
Notes:   All mean ± standard deviations for mean age.Clinical Ophthalmology 2009:3 360
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Acetazolamide 250 mg one tablet one hour preoperatively 
followed by half a tablet 125 mg every eight hours showed 
a statistically significant reduction in the IOP spike post-
operatively at 16, 24, and 48 hours. A previous study 
reported the preoperative use of topical dorzolamide37 and 
a dorzolamide–timolol combination.38 These were effective 
in reducing IOP at six and 24 hours. Another study using 
acetazolamide 500 mg administered at one hour before 
surgery showed significantly reduced IOP at four to six hours 
and 24 hours and fewer pressure spikes above 35 mmHg.39 
However, another study using the same dose one hour after 
surgery found no significant benefit.40
Carbonic anhydrase inhibitors have been used to treat 
glaucoma since 1954, when Becker41 first demonstratez-
the clinical efficacy of acetazolamide. CAIs are sulfon-
amide derivatives that lower IOP by decreasing aqueous 
Table 2 Preoperative and postoperative mean iOP (mmhg)
Time   Mean IOP change (mmHg) + DS (Range)
Control group  Range  Acetazolamide 
group
Range  Dorzolamide 
group
Range  P  Value between groups 
and within groups
Preoperative 12.09 ± 3.19 15 12.08 ± 3.67 16 10.63 ± 2.87 11 0.035
Postoperative
16 hours 16.80 ± 8.04 37 13.11 ± 6.08 24 17.80 ± 8.22 36 0.008
24 hours 11.66 ± 5.11 26 10.61 ± 4.26 22 11.74 ± 5.03 29 0.452
48 hours 10.90 ± 3.65 18 10.01 ± 2.34 13.5 9.75 ± 2.99 18 0.138
Abbreviation: iOP, intraocular pressure.
Table 3 Mean difference iOP change (mmhg) ± se from preoperative to 16, 24, and 48 hours postoperatively
Dependent 
variable
(I) medicine  (J) medicine  Mean 
difference (I–J)
Std 
Error
Sig 
Base iOP Control groups Acetazolamide groups 0.01 0.66 1
Dorzolamide groups 1.46 0.63 0.073
Acetazolamide groups Control groups -0.01 0.66 1
Dorzolamide groups 1.44 0.66 0.093
Dorzolamide groups Control groups -1.46 0.63 0.073
Acetazolamide groups -1.44 0.66 0.093
iOP 16 hours Control groups Acetazolamide groups 3.69 1.54 0.061
Dorzolamide groups -0.98 1.48 0.803
Acetazolamide groups Control groups -3.69 1.54 0.061
Dorzolamide groups -4.67 1.54 0.011
Dorzolamide groups Control groups 0.98 1.48 0.803
Acetazolamide groups 4.67 1.54 0.011
iOP 24 hours Control groups Acetazolamide groups 1.05 0.99 0.57
Dorzolamide groups -0.08 0.96 1
Acetazolamide groups Control groups -1.05 0.99 0.57
Dorzolamide groups -1.13 0.98 0.519
Dorzolamide groups Control groups 0.08 0.95 1
Acetazolamide groups 1.13 0.98 0.519
iOP 48 hours Control groups Acetazolamide groups 0.9 0.63 0.36
Dorzolamide groups 1.15 0.6 0.162
Acetazolamide groups Control groups -0.9 0.63 0.36
Dorzolamide groups 0.25 0.62 0.92
Dorzolamide groups Control groups -1.15 0.6 0.162
    Acetazolamide groups -0.25 0.62 0.92
Note: The mean difference is significant at the 0.05 level.
Abbreviations: iOP, intraocular pressure; se, standard error.Clinical Ophthalmology 2009:3 361
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humor formation. These drugs inhibit carbonic anhydrase, 
which is one of the enzymes that regulate aqueous humor 
formation. Systemic administration of CAIs is extremely 
effective in reducing IOP in most patients but is accompa-
nied by side effects that can range from mild and annoying 
to debilitating and life threatening, the latter necessitating 
discontinuation of these drugs. On rare occasions, CAIs 
may induce irreversible blood dyscrasias, which can be 
fatal. The substantial incidence of side effects and the rare 
occurrence of fatal complications have led to controversy 
regarding the usefulness of and indications for systemi-
cally administered CAIs in the chronic management of 
glaucoma.42 CAIs reduce IOP by inhibiting aqueous humor 
formation. This has been demonstrated with the use of 
indirect measurement techniques43,44 as well as direct fluo-
rophotometric measurement techniques of aqueous humor 
flow rates.45–47 Fluorophotometric studies have documented 
reductions in aqueous humor flow rates of 21% to 40% in 
normal human volunteers and in a few glaucoma patients 
after acute oral dosing with 250 to 750 mg acetazolamide.45–47 
McCannel and colleagues24 found that acetazolamide reduced 
aqueous flow rates by 24% below the nocturnal flow rate 
in the eye of a sleeping patient. Timolol does not produce 
such reactions.
In conclusion, we found that acetazolamide effectively 
reduced the IOP spike, 16 hours and 24 to 48 hours after 
scleral tunnel cataract surgery with hard posterior chamber 
IOL implantation. The mean IOP significantly increased in 
placebo and dorzolamide groups, 16 hours after surgery. IOP 
monitoring in the early postoperative period is still neces-
sary after scleral tunnel cataract surgery with viscoelastic 
substance. It may be possible therefore to select patients at 
greater risk who developed ocular hypertension after cataract 
surgery to receive prophylactic IOP-lowering treatment. This 
would minimize patient morbidity yielding significant health 
economic savings.
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